Clinical Trial Update: Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing safety and efficacy of ReFacto AF in previously untreated Hemophilia A patients in usual care settings; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2019-07-19